These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 20473913)

  • 1. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
    Heiss MM; Murawa P; Koralewski P; Kutarska E; Kolesnik OO; Ivanchenko VV; Dudnichenko AS; Aleknaviciene B; Razbadauskas A; Gore M; Ganea-Motan E; Ciuleanu T; Wimberger P; Schmittel A; Schmalfeldt B; Burges A; Bokemeyer C; Lindhofer H; Lahr A; Parsons SL
    Int J Cancer; 2010 Nov; 127(9):2209-21. PubMed ID: 20473913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catumaxomab: in malignant ascites.
    Frampton JE
    Drugs; 2012 Jul; 72(10):1399-410. PubMed ID: 22676343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.
    Ott MG; Marmé F; Moldenhauer G; Lindhofer H; Hennig M; Spannagl R; Essing MM; Linke R; Seimetz D
    Int J Cancer; 2012 May; 130(9):2195-203. PubMed ID: 21702044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.
    Wimberger P; Gilet H; Gonschior AK; Heiss MM; Moehler M; Oskay-Oezcelik G; Al-Batran SE; Schmalfeldt B; Schmittel A; Schulze E; Parsons SL
    Ann Oncol; 2012 Aug; 23(8):1979-1985. PubMed ID: 22734013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.
    Kurbacher CM; Horn O; Kurbacher JA; Herz S; Kurbacher AT; Hildenbrand R; Bollmann R
    Oncologist; 2015 Nov; 20(11):1333-41. PubMed ID: 26417039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
    Ströhlein MA; Heiss MM
    Future Oncol; 2010 Sep; 6(9):1387-94. PubMed ID: 20919824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study.
    Heiss MM; Ströhlein MA; Bokemeyer C; Arnold D; Parsons SL; Seimetz D; Lindhofer H; Schulze E; Hennig M
    Clin Cancer Res; 2014 Jun; 20(12):3348-57. PubMed ID: 24714773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
    Bokemeyer C
    Expert Opin Biol Ther; 2010 Aug; 10(8):1259-69. PubMed ID: 20624115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catumaxomab: malignant ascites: unjustified marketing authorisation.
    Prescrire Int; 2010 Oct; 19(109):207-9. PubMed ID: 21180374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.
    Sehouli J; Pietzner K; Wimberger P; Vergote I; Rosenberg P; Schneeweiss A; Bokemeyer C; Salat C; Scambia G; Berton-Rigaud D; Santoro A; Cervantes A; Trédan O; Tournigand C; Colombo N; Dudnichenko AS; Westermann A; Friccius-Quecke H; Lordick F
    Med Oncol; 2014 Aug; 31(8):76. PubMed ID: 24965536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
    Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R
    Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.
    Pietzner K; Vergote I; Santoro A; Chekerov R; Marmé F; Rosenberg P; Martinius H; Friccius-Quecke H; Sehouli J
    Med Oncol; 2014 Dec; 31(12):308. PubMed ID: 25367854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).
    Jäger M; Schoberth A; Ruf P; Hess J; Hennig M; Schmalfeldt B; Wimberger P; Ströhlein M; Theissen B; Heiss MM; Lindhofer H
    Cancer Res; 2012 Jan; 72(1):24-32. PubMed ID: 22044753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
    Seimetz D; Lindhofer H; Bokemeyer C
    Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer.
    Petrelli F; Borgonovo K; Lonati V; Elia S; Barni S
    Target Oncol; 2013 Dec; 8(4):291-4. PubMed ID: 23197249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.
    Berek JS; Edwards RP; Parker LP; DeMars LR; Herzog TJ; Lentz SS; Morris RT; Akerley WL; Holloway RW; Method MW; Plaxe SC; Walker JL; Friccius-Quecke H; Krasner CN
    Int J Gynecol Cancer; 2014 Nov; 24(9):1583-9. PubMed ID: 25254563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.
    Seeber A; Braicu I; Untergasser G; Nassir M; Fong D; Botta L; Gastl G; Fiegl H; Zeimet A; Sehouli J; Spizzo G
    Oncotarget; 2015 Sep; 6(28):25017-23. PubMed ID: 26296970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.
    Tsikouras P; Tsagias N; Pinidis P; Csorba R; Vrachnis N; Dafopoulos A; Bouchlariotou S; Liberis A; Teichmann AT; von Tempelhoff GF
    Arch Gynecol Obstet; 2013 Sep; 288(3):581-5. PubMed ID: 23644922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dramatic Response to Catumaxomab Treatment for Malign Ascites Related to Renal Cell Carcinoma With Sarcomotoid Differentiation.
    Pilanc KN; Ordu Ç; Akpnar H; Balc C; Başsülü N; Köksal Üİ; Elbüken F; Okutur K; Bülbül G; Sağlam S; Demir G
    Am J Ther; 2016; 23(4):e1078-81. PubMed ID: 24732906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of catumaxomab in the treatment of malignant ascites.
    Sebastian M
    Cancer Manag Res; 2010 Nov; 2():283-6. PubMed ID: 21188120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.